Clinical use of markers of neurohormonal activation in heart failure;Utilidad clínica de los marcadores neurohormonales en la insuficiencia cardíaca

Revista Espanola de Cardiologia

Volumn 57, Issue 4, 2004, Pages 347-356

  Roig Minguell, Eulalia ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Heart failure; Neurohumoral activation; Ventricular dysfunction

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; PADGEM PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ACCURACY; ADRENERGIC STIMULATION; ARTICLE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; DRUG MECHANISM; HEART FAILURE; HEART HEMODYNAMICS; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HORMONE BLOOD LEVEL; HUMAN; PLASMA RENIN ACTIVITY; PROGNOSIS; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPTOMATOLOGY; BLOOD; CONGESTIVE HEART FAILURE; PHYSIOLOGY; REVIEW;

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RENIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2942693732     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059727     Document Type: Article

References (68)

1. Rodríguez-Artalejo F, Guallar-Castillón P, Banegas Banegas JR, Del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 1997;18:1771-9.
2. Permanyer Miralda G, Soriano N, Brotons C, Moral I, Pinar J, Cascant P, et al. Características basales y determinantes de la evolución en pacientes ingresados por insuficiencia cardí aca en un hospital general. Rev Esp Cardiol 2002;55:571-8.
3. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV. More «malignant» than cancer? Five-year survival following a first admission for heart failure. Eur Heart J 2001;3:315-22.
4. Katz AM. Heart failure. The hemodynamic defense reaction. Pathophysiology, molecular biology and clinical management. Philadelphia: Lippincott, Williams & Wilkins, 2000; p. 109-52.
5. Katz AM. Heart failure. Neurohumoral response II: the inflammatory response. Pathophysiology, molecular biology and clinical management. Philadelphia: Lippincott, Williams & Wilkins, 2000; p. 153-71.
6. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80(11A):L15-25.
7. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-23.
8. Roig E, Pérez-Villa F, Morales M, Jiménez W, Orús J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitors therapy in patients with congestive heart failure. Eur Heart J 2000;21:3-57.
9. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Card 1978;41:233-43.
10. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
11. Bohm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995;25:146-53.
12. Ferrari R, Ceconi C, Curello S, Visioli O. The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J 1998;19(Suppl F):45-51.
13. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996;94:690-7.
14. Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirlin P, et al. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol 1995;75:1151-7.
15. Levine G, Francis G, Goldsmith R, Simon P, Cohn J. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-65.
16. Francis G, Cohn J, Johnson G, Rector T, Goldman S, Simon A, for the V-HeFT Cooperative Studies Group. Plasma norepinephrine, plasma rennin activity, and congestive heart failure. Relations to survival and effects of therapy in V-HeFT. Circulation 1993;87(Suppl VI):40-8.
17. Cohn J, Johnson G, Shabetai R. Loeb H, Tristani F, Rector T, et al, for the V-HeFT Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87:(Suppl VI):5-16.
18. Francis G, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
19. Vidal B, Roig E, Pérez-Villa F, Orús J, Pérez J, Jiménez V, et al. Valor pronóstico de los niveles de citocinas y neurohormonas en la insuficiencia cardíaca severa. Rev Esp Cardiol 2002;55:481-6.
20. Latini R, Masson S, Anand I, Judd D, Maggioni A, Chiang Y, et al, for the Val-HeFT investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation 2002;106:2454-8.
21. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-22.
22. Rouleau JL, Packer M, Moyé L, Champlain J, Bichet D, Klein M, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-91.
23. Vantrimport P, Rouleau JL, Ciampi A, Harel F, De Champain J, Bichet D, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998;19:1552-63.
24. RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomised evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-84.
25. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
27. Jorde U, Ennezat P, Lisker J, Suryadevara V, Infeld J, Cukon S, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-6.
28. Jorde U, Vottorio T, Katz S, Colombo P, Latif F, LeJemtel T. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.
29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-1.
30. Pitt B, Remme W, Zannad F, Neaton J, Martínez F, Roniker B, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
31. Levin ER. Endothelins. N Engl J Med 1995;333:356-62.
32. Clavell A, Stingo A, Marguiles K, Lerman A, Underwood D, Burnett JC. Physiological significance of endothelin. Its role in congestive heart failure. Circulation 1993;87(Suppl V):45-50.
33. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
34. Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, et al. Value of cardiopulmonary exercise testing and big-endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998;32:1695-700.
35. Kinugawa T, Kato M, Ogino K, Osaki S, Igawa O, Hisatome I, Shigemasa C. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Cardiac Heart Failure 2003;9:318-24.
36. Levin ER, Gardner DG, Samson W. Natriuretic peptides. N Engl J Med 1998;339:321-8.
37. Raine A, Erne P, Burgisser E, Muller F, Bolli P, Burkart F, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315:533-7.
38. Gottlieb S, Kubin M, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
39. Johnson W, Omland T, Hall C, Lucas C, Myking O, Collins C, et al. Neurohumoral activation rapidly decreases after intra-venous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002;39:1623-9.
40. Osca J, Quesada A, Arnau MA, Osa A, Hervás I, Almenar L, et al. Péptido cerebral natriurético. Valor diagnó stico en la insuficiencia cardíaca. Rev Esp Cardiol 2002;55:7-15.
41. Salomone O. Los péptidos natriuréticos en la insuficiencia cardíaca: mejorando el diagnóstico y el manejo del síndrome. Rev Esp Cardiol 2002;55:4-6.
42. Lemos J, McGuire D, Drazner M. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
43. Morrison L, Harrison A, Krishnaswamy P, Kazanegra R, Copton P, Masiel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
44. Cheng V, Kazanagra R, García A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
45. Masiel A, Krishnaswamy P, Kazanagra R, Clopton P, Gardetto N, Morrisey R, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
46. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayasi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J 1999;20:1799-807.
47. Koglin J, Pehlivandi S, Schwaiblmair M, Vogeser M, Cremer P, Scheit W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
48. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
49. O'Brien R, Squire I, Demme B, Davies J, Leong L. Pre-discharge, but not admission levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003;5:499-506.
50. Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon, Golmard JL, et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 2000;21:1009-14.
51. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
52. Baumgarten G, Knuefermann P, Kalra D, Gao F, Taffet GE, Michael L, et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 2002;105:2192-7.
53. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
54. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
55. Orus J, Roig E, Pérez Villa F, Paré C, Azqueta M, Filella X, et al. Prognostic value of serum citoquines in patients with congestive heart failure. J Heart Lung Transplant 2000;19:419-25.
56. Rauchhaus M, Doehner W, Francis D, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
57. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001;37:412-7.
58. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31: 391-8.
59. Roig E, Orus J, Pare C, Azqueta M, Filella X, Pérez-Villa F, et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:688-90.
60. Yin W, Chen J, Jen H, Chiang M, Huang W, Feng A, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Failure 2003;5:507-16.
61. Tsutamoto T, Hisanaga T, Fukai D. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995;76:803-8.
62. Ferrari R, Agnoletti L, Comini L, Gaia G, Bachetti T, Cargnoni A, et al. Oxidative stress during myocardial ischaemia and heart failure. Eur Heart J 1998;19(Suppl 13):2-11.
63. Tatsumi T, Matoba S, Kawahara A, Keira N, Shiraishi J, Akashi K, et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 2000;35:1338-46.
64. Tatsumi T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002;39:957-62.
65. Anker S, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7.
66. Node K, Fujita M, Kitakaze M, Hori M, Liao J. Short-term statin improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
67. Setsuta K, Seino Y, Takahasi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-10.
68. Horwich T, Patel J, McLellan R, Fonarow G. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction and increased mortality rates in advanced heart failure. Circulation 2003;108:833-8.